$AKBA
Akebia Therapeutics, Inc.
XNAS•Health Care•Pharmaceutical Preparations
$0.861
▼-1.15%-$0.010
Subscriptions are live. Early access $24.99/mo, or start with 5 free premium days.
Plans & pricingDonateAkebia Therapeutics, Inc.
XNAS•Health Care•Pharmaceutical Preparations
Why is AKBA down today? It is at $0.861 (-1.15%), and our scanner flagged it 62 times on unusual volume this month. See the catalyst behind the move, real-time alerts the moment AKBA spikes, and full due diligence on AKBA — key stats, earnings, dilution and insider activity. Free.
Our scanner flagged $AKBA 62 times in the last 30 days. Create a free account to track $AKBA, build a watchlist, and get instant unusual-volume alerts, with a full day of premium now and 5 more when you verify your email, no card needed.
No card · 5 premium days · join 800+ traders
The top plays and unusual-volume catches our scanner flags, emailed to you. No account needed.
No spam. Unsubscribe anytime. Not investment advice.
Here is the latest on AKBA from our scanner (live price and day move above). We have not detected an unusual-volume catalyst for AKBA today, so it is trading in line with its recent range. The moment our scanner flags unusual activity, the reason will appear here.
| Insider | Action | Shares | % of position | Owns after | Value | Date |
|---|---|---|---|---|---|---|
Butler John P. Officer | Other | 350K 0.1% of company | added 10% | 3.72M | $221K at $0.630 | Aug 6, 26 |
Ostrowski Erik Officer | Sold (automatic/other) | -56K 0.02% of company | sold 8.3% | 617K | $62K at $1.11 | Jun 29, 26 |
Adams Adrian Director | Acquired (grant/award) | +36K 0.01% of company | added 18% | 236K | n/a | Jun 17, 26 |
Zumwalt Leanne M Director | Acquired (grant/award) | +36K 0.01% of company | added 33% | 145K | n/a | Jun 17, 26 |
Frieson Ron Director | Acquired (grant/award) | +36K 0.01% of company | added 28% | 165K | n/a | Jun 17, 26 |
Rogers Michael W Director | Acquired (grant/award) | +36K 0.01% of company | added 22% | 197K | n/a | Jun 17, 26 |
Smith Cynthia Director | Acquired (grant/award) | +36K 0.01% of company | added 22% | 197K | n/a | Jun 17, 26 |
Wolf Myles Director | Acquired (grant/award) | +36K 0.01% of company | added 27% | 169K | n/a | Jun 17, 26 |
Butler John P. Officer | Bought (open market) | +69K 0.02% of company | added 2.1% | 3.37M | $87K at $1.25 | Mar 4, 26 |
Butler John P. Officer | Acquired (grant/award) | +175K 0.06% of company | added 5.5% | 3.38M | $247K at $1.41 | Feb 2, 26 |
Butler John P. Officer | Sold (automatic/other) | -341K 0.1% of company | sold 9.6% | 3.21M | $474K at $1.39 | Feb 2, 26 |
Ostrowski Erik Officer | Sold (automatic/other) | -35K 0.01% of company | sold 4.9% | 673K | $49K at $1.39 | Feb 2, 26 |
Recent Form-4 filings via Nasdaq. Open-market buys are the signal worth watching. Grants and automatic (10b5-1) sells are routine. “% of position” is the share of that insider’s own holding the trade moved. Not investment advice.
Blend of news sentiment, today’s move, and community votes. Not investment advice.
News, unusual-volume alerts, AI-trader trades and community chatter - the whole story, newest first.
Comparable names in pharmaceutical preparations, closest in size first.
Here is the latest on AKBA from our scanner (live price and day move above). We have not detected an unusual-volume catalyst for AKBA today, so it is trading in line with its recent range. The moment our scanner flags unusual activity, the reason will appear here.
AKBA last traded at $0.861, down 1.15% on the day. The price and chart above update live during market hours (4 AM to 8 PM ET).
Akebia Therapeutics, Inc. (AKBA) is next expected to report earnings on Monday, November 9, 2026, about 36 days away. Earnings reports often cause large overnight gaps, so many traders manage risk around the date. The date can shift until the company officially confirms it.
The AKBA Live Alerts panel on this page streams real-time unusual volume (RVOL), momentum, halt and 200-EMA alerts from our scanner the moment they fire. Our scanner has flagged AKBA 62 times in the last 30 days.
AKBA (Akebia Therapeutics, Inc.) trades on XNAS, with a market cap of about $240M in the Pharmaceutical Preparations sector.
That depends on your strategy and risk. Day traders look for volume, volatility and a clear trend. Use the live chart, RVOL alerts and 200-EMA context on this page to judge AKBA for yourself. This is not investment advice.
Live data from TheDesperateTrader scanner. Not investment advice.
$AKBA discussion
Sign in to ask a question or join the discussion.